PO Box 1488
Warrenville, IL 60555
Phone: 331.248.7888
Email: sidp@affinity-strategies.com
Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) review expanded MERINO trial data including mortality by pathogen MIC, PK-PD principles, BLING III, beta-lactam therapeutic drug monitoring, linezolid dosing in renal impairment, microbiology issues, and updates from EUCAST.
CORRECTION: Piperacillin-tazobactam was dosed 4.5g IV every 6 hours in the Merino trial.
Ryan Shields, PharmD, MS
Dr. Ryan Shields is an Associate Professor of Medicine at the University of Pittsburgh School of Medicine and Co-Director of the Antibiotic Management Program at UPMC Presbyterian Hospital. Dr. Shields completed his pharmacy practice residency at Saint Louis University Hospital followed by infectious diseases pharmacy residency at the University of Pittsburgh. His research and clinical interests include antimicrobial drug resistance, especially in gram-negative bacteria and yeast.
